Aignostics

Company profile

About Aignostics

Aignostics is a Berlin and New York-based AI company transforming drug development and patient outcomes through advanced pathology analytics. As a spin-off from Charité Berlin, one of Europe's largest university hospitals, Aignostics has built industry-leading foundation models in collaboration with Mayo Clinic to analyze complex biomedical data at scale. The company's flagship product, Atlas H&E-TME, provides comprehensive tumor microenvironment profiling from H&E-stained whole slide images at single-cell resolution. Powered by Atlas 2, their latest foundation model co-developed with Mayo Clinic, the platform delivers over 4,500 quantitative metrics per image including cell detection and classification across 9 cell types, tissue segmentation into 7 regions, and spatial network analysis. The solution currently supports eight primary cancer types with validated performance on at least 90% of invasive morphological subtypes. Aignostics offers both products and custom services spanning target and biomarker discovery, translational research, and digital diagnostics. The company maintains proprietary access to pathology samples and multimodal data from over 30 million patients at leading university hospitals and laboratories. Their interdisciplinary team combines data scientists, machine learning engineers, pathologists, and biologists to deliver validated solutions for biopharma companies and academic researchers. The company is ISO 13485 and ISO 27001 certified with a GCP-ready clinical trial platform.

Company description · Aignostics official website